BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Clinical trial supply company strengthens its presence in the European Union
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Subscribe To Our Newsletter & Stay Updated
